{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-249830","form_type":"8-K","ticker":null,"cik":"0001597553","company_name":"Sage Therapeutics, Inc.","filed_at":"2024-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.921122+00:00","generated_at":"2026-05-30T06:56:51.146574+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Sage Therapeutics CFO and GC depart as part of workforce reorganization; separation agreements signed","bullets":["CFO Kimi Iguchi and GC Anne Marie Cook resigned on Oct 31, 2024, as part of a previously announced workforce reorganization.","Iguchi receives 12-month salary continuation, COBRA, and a prorated 50% bonus; also enters consulting agreement through Mar 31, 2025, with hourly pay.","Cook receives similar severance (12-month salary continuation, COBRA, prorated 50% bonus); no consulting agreement.","Equity awards amended: for Iguchi, vesting continues during consulting and exercise extended to Oct 31, 2025; for Cook, exercise extended to same date."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-249830","json":"https://secwatch.observer/filing/0001193125-24-249830.json","markdown":"https://secwatch.observer/filing/0001193125-24-249830.md","text":"https://secwatch.observer/filing/0001193125-24-249830.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524249830/0001193125-24-249830-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524249830/d843349d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:56:51.146574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b727dc470","claim":"Anne Marie Cook resigned as Senior Vice President, General Counsel and Secretary at Sage Therapeutics, Inc..","evidence_excerpt":"On the Separation Date, Anne Marie Cook and the Company entered into a separation agreement (the “Cook Separation Agreement”) providing for the resignation of Ms. Cook from her positions as Senior Vice President, General Counsel and Secretary of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524249830/0001193125-24-249830-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Senior Vice President, General Counsel and Secretary"}],"fact_type":"executive_change"},{"claim_id":"dd5f2eff07","claim":"Kimi Iguchi resigned as Chief Financial Officer and Treasurer at Sage Therapeutics, Inc..","evidence_excerpt":"On October 31, 2024 (the “Separation Date”), Kimi Iguchi and Sage Therapeutics, Inc. (the “Company”) entered into a separation agreement (the “Iguchi Separation Agreement”) providing for the resignation of Ms. Iguchi from her positions as the Chief Financial Officer and Treasurer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1597553/000119312524249830/0001193125-24-249830-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}